Drug Profile

Research programme: tyrosine protein kinase antibody therapeutics - ElsaLys Biotech

Alternative Names: Anti-TYRO3/MERKT antibody - ElsaLys Biotech; ELB 031

Latest Information Update: 11 May 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ElsaLys Biotech
Developer Curie Institute; ElsaLys Biotech
Class Antibodies
Mechanism of Action Proto-oncogene protein c-mer modulators; TYRO3 receptor protein tyrosine kinase modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

07 May 2020 ElsaLys Biotech has been acquired by Mediolanum
28 Oct 2019 No recent reports of development identified for preclinical development in Solid-tumours in France (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com